IL291569B2 - Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-4,2,1-triazol-3-amine - Google Patents

Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-4,2,1-triazol-3-amine

Info

Publication number
IL291569B2
IL291569B2 IL291569A IL29156922A IL291569B2 IL 291569 B2 IL291569 B2 IL 291569B2 IL 291569 A IL291569 A IL 291569A IL 29156922 A IL29156922 A IL 29156922A IL 291569 B2 IL291569 B2 IL 291569B2
Authority
IL
Israel
Prior art keywords
formula
chlorobenzyl
compound
solvent
piperidin
Prior art date
Application number
IL291569A
Other languages
English (en)
Hebrew (he)
Other versions
IL291569B1 (en
IL291569A (en
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of IL291569A publication Critical patent/IL291569A/en
Publication of IL291569B1 publication Critical patent/IL291569B1/en
Publication of IL291569B2 publication Critical patent/IL291569B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL291569A 2019-09-25 2020-09-25 Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-4,2,1-triazol-3-amine IL291569B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905494P 2019-09-25 2019-09-25
PL43126919 2019-09-25
PCT/IB2020/058984 WO2021059220A1 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine

Publications (3)

Publication Number Publication Date
IL291569A IL291569A (en) 2022-05-01
IL291569B1 IL291569B1 (en) 2024-12-01
IL291569B2 true IL291569B2 (en) 2025-04-01

Family

ID=73139065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291569A IL291569B2 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-4,2,1-triazol-3-amine

Country Status (16)

Country Link
US (2) US11746107B2 (https=)
EP (1) EP4041726B8 (https=)
JP (1) JP7697933B2 (https=)
KR (1) KR20220069008A (https=)
CN (1) CN114466845B (https=)
AU (1) AU2020356534B2 (https=)
BR (1) BR112022005420A2 (https=)
CA (1) CA3155177A1 (https=)
ES (1) ES3056105T3 (https=)
IL (1) IL291569B2 (https=)
MX (1) MX2022002881A (https=)
PH (1) PH12022550713A1 (https=)
PL (1) PL4041726T3 (https=)
TW (3) TWI769532B (https=)
WO (1) WO2021059220A1 (https=)
ZA (1) ZA202204542B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
ATE354568T1 (de) * 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
PE20142366A1 (es) * 2012-05-30 2015-01-10 Hoffmann La Roche Compuestos triazolo como inhibidores de pde 10
EP3082805B1 (en) * 2013-12-20 2020-02-05 Institute for Drug Discovery, LLC Substituted amino triazoles, and methods using same
US9440953B2 (en) 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
PL415078A1 (pl) * 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX2022000306A (es) 2019-07-15 2022-03-11 Oncoarendi Therapeutics Sa Amino triazoles sustituidos utiles como inhibidores de quitinasa.
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Also Published As

Publication number Publication date
JP2022549863A (ja) 2022-11-29
PL4041726T3 (pl) 2026-02-23
ZA202204542B (en) 2023-01-25
EP4041726B1 (en) 2025-09-17
EP4041726A1 (en) 2022-08-17
CN114466845B (zh) 2024-12-17
IL291569B1 (en) 2024-12-01
EP4041726C0 (en) 2025-09-17
TW202448877A (zh) 2024-12-16
IL291569A (en) 2022-05-01
PH12022550713A1 (en) 2024-02-12
JP7697933B2 (ja) 2025-06-24
WO2021059220A1 (en) 2021-04-01
CA3155177A1 (en) 2021-04-01
EP4041726B8 (en) 2025-11-26
US20210147401A1 (en) 2021-05-20
CN114466845A (zh) 2022-05-10
TW202126644A (zh) 2021-07-16
TWI769532B (zh) 2022-07-01
US20240025889A1 (en) 2024-01-25
BR112022005420A2 (pt) 2022-06-21
AU2020356534A1 (en) 2022-05-19
TWI849432B (zh) 2024-07-21
ES3056105T3 (en) 2026-02-18
US11746107B2 (en) 2023-09-05
US12319677B2 (en) 2025-06-03
MX2022002881A (es) 2022-06-08
AU2020356534B2 (en) 2026-04-09
KR20220069008A (ko) 2022-05-26
TWI892762B (zh) 2025-08-01
TW202237594A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
AU2004309164B2 (en) Triazole derivatives as vasopressin antagonists
US8093400B2 (en) Compounds useful in therapy
AU2004260756B2 (en) Indazole derivatives
CA2730793C (en) Azole compound
CA2753434A1 (en) Soluble guanylate cyclase activators
NL1030961C2 (nl) Gesubstitueerde triazoolderivaten als oxytocineantagonisten.
AU4295300A (en) Substituted azoles
JP2000086657A (ja) 5−アミノイソキサゾール誘導体
IL291569B2 (en) Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-4,2,1-triazol-3-amine
AU2005213538A1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
CA2737299C (en) Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof
CA2940047A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
TWI660955B (zh) 製備噻唑衍生物之方法
EP2423204A1 (en) Thiazolidinone derivative
WO2013084241A1 (en) Compounds as inhibitors of renin
JP2022549863A5 (https=)
CN110698395A (zh) 一种托吡司特的中间体的制备方法
CN107383068A (zh) 噻唑并三氮唑‑6‑乙酰胺类衍生物及应用
EP1917257A1 (en) Substituted triazole derivatives as oxytocin antagonists
JP5064872B2 (ja) N−(2−アミノ−1,2−ジシアノビニル)イミデート類の製造方法
JP2012516327A (ja) カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
CN111247127B (zh) 用于合成药物的中间体化合物的生产方法
CN111868031B (zh) N-烷氧基羰基哌啶衍生物的制备方法及其中间体
ES2364254T3 (es) Piperidinilcarbonil pirrolidinas y su uso como agonistas de melanocortina.
Voskiene et al. Products from condensation of 1-(3 (4)-acetylphenyl)-4-carboxy-2-pyrrolidinones with o-phenylenediamine and their properties